The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 190.00
Bid: 185.00
Ask: 195.00
Change: 5.00 (2.70%)
Spread: 10.00 (5.405%)
Open: 185.00
High: 192.50
Low: 185.00
Prev. Close: 185.00
SNX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-Close Statement

10 Apr 2006 07:01

Synexus Clinical Research PLC10 April 2006 Synexus Clinical Research plc ("Synexus" or "the Company") Pre-Close Trading Statement Synexus, the clinical trials services group, today announces the followingpre-close trading update ahead of its preliminary results for the year to 31March 2006. Further to the four months trading results reported in its AIM admissiondocument issued in November 2005, the Company is pleased to report that tradinghas continued to be buoyant and that results for the year to 31 March 2006 aretherefore anticipated to be in line with management expectations. Since its flotation, Synexus has vigorously pursued its stated strategy oforganic growth combined with strategic partnerships and acquisitions to expandits business into emerging economies. To this end, Synexus has established thefirst Site Management Organisation in India through a strategic alliance withthe Indian Clinical Research Institute. Furthermore, in January 2006, theCompany acquired the Polish clinical trials business Skandynawskie CentrumMedyczne Sp. z.o.o. ("SCM"). This acquisition will allow Synexus to exploit thegrowing opportunities for clinical trials and patient recruitment in Central andEastern European markets. The Company continues to pursue a number of other opportunities to replicate itsbusiness in new territories with particular emphasis on those within Central andEastern Europe and has a number of potential targets currently under review. TheCompany is strengthening its management team at the senior operational level,broadening its skills base and providing further capability to support itsgrowth, both in emerging clinical trial markets and in the UK. Enquiries for our services remain strong and the forward order book coversaround 60% of the current market estimate of income for the year ending 31 March2007. Synexus expects to announce its preliminary results for the year to 31 March2006 on 6 June 2006. Press enquiries Synexus Clinical Research plc Tel: +44 (0)1257 230 723Michael Fort, Chief Executive Biddicks - Financial Public Relations Tel: +44 (0)20 7448 1000Zoe Biddick This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th May 20227:00 amRNSDirector/PDMR Shareholding
20th Apr 202212:05 pmRNSResult of AGM
20th Apr 20227:00 amRNSAGM Statement
4th Apr 202210:47 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSPosting of Accounts and Notice of AGM
8th Mar 20227:00 amRNSLong Term Infrastructure Contract
4th Mar 20227:00 amRNSAvailability of Annual Report and Accounts
22nd Feb 20227:00 amRNSFinal Results
16th Feb 20227:36 amRNSInvestor Presentation
2nd Feb 20227:00 amRNSNotification of Final Results
14th Dec 20217:00 amRNSContract for New Buses in Northern Ireland
8th Dec 20217:00 amRNSTrading Update
3rd Nov 20217:00 amRNSNew Casino Projects in North America
28th Oct 20217:00 amRNSMajor Project for West Midlands Police
1st Oct 20212:15 pmRNSDirector/PDMR Shareholding
23rd Aug 20217:00 amRNSContract Award for New Refinery Project
13th Jul 20217:00 amRNSHalf-year Report
14th Jun 20217:00 amRNSTrading Update
2nd Jun 20217:00 amRNSDirector/PDMR Shareholding
28th May 20217:00 amRNSDirector/PDMR Shareholding
11th May 20217:00 amRNSHolding(s) in Company
27th Apr 202111:22 amRNSResult of AGM
27th Apr 20217:00 amRNSBusiness Update
23rd Apr 20214:23 pmRNSHolding(s) in Company
7th Apr 20211:08 pmRNSDirector/PDMR Shareholding
7th Apr 20217:00 amRNSSynectics secures major City of London project
31st Mar 20217:00 amRNSHolding(s) in Company
23rd Mar 20217:00 amRNSPosting of Accounts and Notice of AGM
17th Mar 20217:00 amRNSDirector’s/PCA’s Interest in Shares
4th Mar 20217:00 amRNSPDMR’s Interest in Shares
2nd Mar 20217:00 amRNSFinal Results
17th Feb 20217:00 amRNSFurther contract wins in Irish bus market
10th Feb 20217:00 amRNSLetter of Intent and Notification of Results Date
7th Jan 20217:00 amRNSSynectics’ S-Bahn project goes live
15th Dec 20207:00 amRNSTrading Update
1st Dec 20207:00 amRNSSynectics appoints Dr Kerstin Wendt
26th Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:36 amRNSDirector/PDMR Shareholding
18th Nov 202011:53 amRNSDirector/PDMR Shareholding
17th Nov 20207:00 amRNSContract Win
2nd Oct 202011:02 amRNSDirector/PDMR dealings
29th Sep 20207:00 amRNSTrading Update
12th Aug 20207:00 amRNSDirector/PDMR Shareholding
10th Aug 20207:00 amRNSDirectors' / PDMRs' Interests in Shares
30th Jul 20202:03 pmRNSDirector/PDMR Shareholding
28th Jul 20207:00 amRNSDirector/PDMR Shareholding
28th Jul 20207:00 amRNSContract Wins for 'next generation' Irish Buses
27th Jul 20204:40 pmRNSSecond Price Monitoring Extn
27th Jul 20204:35 pmRNSPrice Monitoring Extension
27th Jul 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.